Clinical Trial: A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Brief Summary: A study of ASP2151 in subjects with recurrent outbreaks of genital herpes.
Detailed Summary:
Sponsor: Astellas Pharma Inc
Current Primary Outcome: To compare the efficacy and safety of ASP2151 with valacyclovir and placebo in the acute treatment of recurrent genital Herpes Simplex Virus Infection [ Time Frame: 17 days ]
Original Primary Outcome: To compare the efficacy and safety of ASP2151 with valacyclovir and placebo in the acute treatment of recurrent genital Herpes Simplex Virus Infection
Current Secondary Outcome: Pharmacokinetics in study patients [ Time Frame: 4 days ]
Original Secondary Outcome: Pharmacokinetics in study patients
Information By: Astellas Pharma Inc
Dates:
Date Received: June 12, 2007
Date Started: June 2007
Date Completion:
Last Updated: February 27, 2013
Last Verified: February 2013